Disposition of 13508 shares by Loscalzo Joseph of Ionis Pharmaceuticals at 37.861 subject to Rule 16b-3
| IONS Stock | USD 35.73 0.17 0.47% |
Slightly above 56% of Ionis Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Ionis Pharmaceuticals suggests that many traders are alarmed. Ionis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Ionis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Ionis |
Filed transaction by Ionis Pharmaceuticals Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at investing.com
 |
Ionis Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
44
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ionis Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ionis Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Ionis Pharmaceuticals Historical Investor Sentiment
Investor biases related to Ionis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ionis. The trend in average sentiment can be used to explain how an investor holding Ionis can time the market purely based on public headlines and social activities around Ionis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ionis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ionis Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ionis Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Ionis Pharmaceuticals.
Ionis Pharmaceuticals Fundamental Analysis
We analyze Ionis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ionis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ionis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Ionis Pharmaceuticals is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Ionis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ionis Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Ionis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ionis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Ionis Pharmaceuticals Related Equities
| EXEL | Exelixis | 1.48 | ||||
| BMRN | Biomarin Pharmaceutical | 0.93 | ||||
| KRYS | Krystal Biotech | 0.26 | ||||
| AKRO | Akero Therapeutics | 0.22 | ||||
| ALNY | Alnylam Pharmaceuticals | 0.26 | ||||
| ARWR | Arrowhead Pharmaceuticals | 0.46 | ||||
| HALO | Halozyme Therapeutics | 0.56 | ||||
| APLS | Apellis Pharmaceuticals | 0.62 | ||||
| IOVA | Iovance Biotherapeutics | 0.85 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
| INCY | Incyte | 1.14 | ||||
| TERN | Terns Pharmaceuticals | 1.58 | ||||
| PTCT | PTC Therapeutics | 2.73 | ||||
| VKTX | Viking Therapeutics | 2.88 | ||||
| SRPT | Sarepta Therapeutics | 3.33 |
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.